Efficacy Study of Dasatinib in Locally Advanced Triple-Negative Breast Cancer Patients

NCT00817531 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

OTHER

Sponsor class

Stopped terminated due to futility after interim analysis

Conditions

Breast Cancer

Interventions

DRUG: Dasatinib

Sponsor

Baylor Breast Care Center

Collaborators

[object Object]